| BORG, Christophe |
| Recruiting | 3 | 918 | Europe, Canada, Japan, RoW | Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil | Jazz Pharmaceuticals, BeiGene, Ltd. | Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma | 05/25 | 05/26 | | |
| Not yet recruiting | 3 | 244 | NA | Avastin, 25 Mg/mL Intravenous Solution, Experimental group, Control group | University Hospital, Tours, CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, CHU de Clermont-Ferrand, CHU de Reims, CHU de Brest, AP-HP, Hôpital Pitié- Salpétrière, CHU de Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, AP-HP, Hôpital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, CHU de Nancy | Unresectable Metastatic Colorectal Cancer | 10/28 | 10/29 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
| Recruiting | 3 | 800 | Europe | Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine | UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament | Biliary Tract Neoplasms | 06/27 | 06/28 | | |
REPROGRAM-02, NCT05462613: Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer |
|
|
| Recruiting | 2/3 | 446 | Europe | quality of life questionnaires, Blood sample, Regorafenib, Metronomic chemotherapies, Aspirin, Bevacizumab, FOLFIRI or FOLFOX | Centre Hospitalier Universitaire de Besancon | Metastatic Colorectal Cancer | 11/29 | 11/30 | | |
APACaPOp, NCT03400072: Adapted Physical Activity in Patients With Resected Pancreatic Cancer ( PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial |
|
|
| Recruiting | 2 | 252 | Europe | Unsupervised APA program, Supervised APA program | Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group | Pancreas Cancer, Quality of Life | 02/22 | 08/24 | | |
| Active, not recruiting | 2 | 106 | Europe | Durvalumab, MEDI4736, Tremelimumab, CP-675 | GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca | Advanced Biliary Tract Carcinoma | 07/22 | 12/24 | | |
| Active, not recruiting | 2 | 99 | Europe | MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil | GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG | Anal Cancer | 02/23 | 12/24 | | |
| Completed | 2 | 77 | Europe | DONEPEZIL, PLACEBO | University Hospital, Clermont-Ferrand, Federation Francophone de Cancerologie Digestive | Digestive Oncology, Supportive Care | 01/24 | 01/24 | | |
MAZEPPA, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status. |
|
|
| Active, not recruiting | 2 | 307 | Europe | Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan | GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca | Metastatic Pancreatic Adenocarcinoma | 07/23 | 12/24 | | |
SPARTANA, NCT04894370: Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma |
|
|
| Recruiting | 2 | 34 | Europe | Sample collection | Centre Hospitalier Universitaire de Besancon, National Cancer Institute, France, Novartis | Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma | 06/25 | 11/26 | | |
| Active, not recruiting | 2 | 352 | Europe, Canada, US | tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin | Seagen Inc., Genmab, Merck Sharp & Dohme LLC | Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck | 02/26 | 11/26 | | |
CLavSyn, NCT03117972: Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels |
|
|
| Terminated | 2 | 54 | Europe | FOLFOXIRI, Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, FOLFOX, FOLFIRI, Ironotecan, Bevacizumab, LV5FU2, Capecitabine | Centre Hospitalier Universitaire de Besancon | Metastatic Colorectal Cancer | 08/24 | 11/24 | | |
TEDOPAM, NCT03806309: Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma |
|
|
| Recruiting | 2 | 106 | Europe | FOLFIRI, Leucovorin (Folinic Acid), Fluorouracil, Irinotecan, OSE2101, Tedopi | GERCOR - Multidisciplinary Oncology Cooperative Group, OSE Immunotherapeutics | Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer | 12/23 | 12/24 | | |
| Active, not recruiting | 2 | 234 | Europe, US, RoW | Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care | Agenus Inc. | Metastatic Colorectal Cancer | 02/25 | 07/25 | | |
ALIX, NCT03974854: Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma |
|
|
| Terminated | 2 | 25 | Europe | XELOXIRI-3, Capecitabine, Oxaliplatine, Irinotecan, Gemcitabine | Centre Hospitalier Universitaire de Besancon | Metastatic Pancreatic Adenocarcinoma | 08/23 | 02/24 | | |
INTERACT-ION, NCT04719988: Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma. |
|
|
| Active, not recruiting | 2 | 55 | Europe | Blood sample collection, Biopsy | Centre Hospitalier Universitaire de Besancon, Boehringer Ingelheim | Squamous Cell Carcinoma of the Anus Stage III | 11/24 | 07/26 | | |
CARE, NCT06425133: Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers |
|
|
| Recruiting | 2 | 174 | Europe | Blood sample, Quality of life questionnaires, Biopsy, Regorafenib, Regorafenib + metronomic chemotherapy | Centre Hospitalier Universitaire de Besancon, Groupement Interrégional de Recherche Clinique et d'Innovation | Metastatic Colorectal Cancer | 09/27 | 09/28 | | |
VolATIL, NCT03946358: Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers |
|
|
| Completed | 2 | 47 | Europe | Blood sample collection, Tumor biopsies, CT scan, Atezolizumab, anti-PD-L1, UCPVax, Vaccine | Centre Hospitalier Universitaire de Besancon, Roche Pharma AG, National Cancer Institute, France | Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer, Cervical Cancer | 03/24 | 11/24 | | |
| Recruiting | 2 | 72 | Europe | Nivolumab 10 MG/ML Intravenous Solution, Regorafenib 30 MG Oral Tablet, Radiotherapy, Surgery, Non-operative Management | Jules Bordet Institute | Rectal Cancer Stage II, Rectal Cancer Stage III | 01/26 | 12/30 | | |
FUDOSE, NCT06475352: Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme |
|
|
| Recruiting | 2 | 400 | Europe | FOLFOX regimen, CAPOX regimen | UNICANCER | Digestive Cancer, Colorectal Cancer | 04/27 | 01/30 | | |
TRIFLUOX-DP, NCT06245356: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer |
|
|
| Not yet recruiting | 2 | 73 | Europe | Lonsurf, Oxaliplatin, Panitumumab, Bevacizumab, Trastuzumab, Nivolumab | UNICANCER, Servier | Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency | 10/26 | 10/28 | | |
TERTIO, NCT05528952: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 105 | Europe | Atezolizumab, Bevacizumab, UCPVax | Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group, PRODIGE | Hepatocellular Carcinoma | 04/25 | 09/27 | | |
LOGICAN, NCT05476796 / 2022-000273-81: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer |
|
|
| Recruiting | 2 | 118 | Europe | Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO | UNICANCER, Servier | Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 01/26 | 01/27 | | |
NCT05983367: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer |
|
|
| Active, not recruiting | 2 | 70 | Europe | Ompenaclid, RGX-202-01, Placebo, Bevacizumab, FOLFIRI regimen | Inspirna, Inc. | Colorectal Cancer, Metastatic Colon Cancer | 09/25 | 12/26 | | |
| Active, not recruiting | 2 | 154 | Europe, Canada, Japan, US, RoW | Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A | GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd | Neoplasms, Rectal | 11/26 | 10/29 | | |
| Recruiting | 2 | 96 | Europe | Nivolumab 480mg + Ipilimumab, Opdivo, Yervoy, Nivolumab 240 mg + Ipilimumab | GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb | Colorectal Cancer Metastatic, MSI-H Colorectal Cancer | 04/27 | 04/28 | | |
TASKIN, NCT05201352: Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine |
|
|
| Recruiting | 1/2 | 160 | Europe | trifluridine/tipiracil + XB2001, trifluridine/tipiracil + placebo | Centre Georges Francois Leclerc | Metastatic Colorectal Cancer | 10/26 | 10/26 | | |
| Recruiting | 1/2 | 374 | Europe, Canada, Japan, US, RoW | Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil | Takeda, Takeda Development Center Americas, Inc. (TDC Americas) | Solid Neoplasms | 01/26 | 01/26 | | |
| Active, not recruiting | 1/2 | 42 | Europe, US | EO4010, Nivolumab, Bevacizumab | Enterome, Enterome SA | Colorectal Cancer Metastatic | 02/26 | 02/26 | | |
Epitopes-CRC01, NCT02838381: Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer |
|
|
| Completed | N/A | 553 | Europe | Additional biological samples | Centre Hospitalier Universitaire de Besancon | Metastatic Cancer | 12/23 | 06/24 | | |
PREDICT-IRFC, NCT04767568: Exploratory Study of the Relevance of a Blood Test in the Management of Patients in the Context of Colorectal Cancer Screening |
|
|
| Recruiting | N/A | 400 | Europe | Blood sample, Tumor tissue, stool collection | Centre Hospitalier Universitaire de Besancon | Colorectal Cancer | 08/25 | 09/28 | | |
Pancreas-CGE, NCT02818907: Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable |
|
|
| Completed | N/A | 290 | Europe | Additional biological samples | Centre Hospitalier Universitaire de Besancon, Cancéropôle Grand-Est | Pancreatic Cancer | 07/23 | 07/23 | | |
NCT06515821: Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods |
|
|
| Recruiting | N/A | 4100 | Europe, RoW | ONCOSCREEN | Firalis SA, University Medical Center Mainz | Colorectal Cancer | 12/26 | 12/26 | | |
HORIZON, NCT06626269: Identification of Innovative Biomarkers Related to the Immune System or Tumor Microenvironment to Promote the Efficacy of Immunotherapies |
|
|
| Not yet recruiting | N/A | 700 | Europe | Blood sample, Tumor tissue | Centre Hospitalier Universitaire de Besancon | Advanced Digestive Cancer, Advanced Gynecologic Cancer | 01/30 | 01/32 | | |
| Recruiting | N/A | 232 | Europe | | GERCOR - Multidisciplinary Oncology Cooperative Group | Metastatic Colorectal Cancer, Circulating Tumor DNA | 09/25 | 06/27 | | |
| Recruiting | N/A | 172 | Europe | Blood sampling | Institut Curie | HPV Positive Pelvic Cancer | 06/26 | 06/26 | | |
| Borot, Sophie |
ISLET CHIP, NCT03067324: Quality Control of Pancreatic Islet Intended to Islet Graft Cells Intended to Stabilot Islet Graft Protocol |
|
|
| Recruiting | N/A | 40 | Europe | | University Hospital, Grenoble, University Hospital, Bordeaux | Pancreatic Islet Quality Control | 12/20 | 07/21 | | |
ApoC1, NCT02816099: Influence of Glycaemic Balance on the Ability of Apolipoprotein C1 to Inhibit Cholesteryl Ester Transfer Protein in Type-1 Diabetes Patients |
|
|
| Completed | N/A | 206 | Europe | Prise de sang | Centre Hospitalier Universitaire Dijon | diabète de Type 1 | 11/22 | 11/22 | | |
ACTIDIANE, NCT03184662: Efficacy of a High-intensity Physical Activity Program on Renal Function in High Risk Patients With Type 2 Diabetes |
|
|
| Recruiting | N/A | 300 | Europe | HIPA, Counseling PA | Poitiers University Hospital, University Hospital, Bordeaux, University Hospital, Clermont-Ferrand, Centre Hospitalier Universitaire Dijon, Centre Hospitalier Universitaire de Besancon, Hopital Lariboisière, Bichat Hospital, Centre Hospitalier Sud Francilien, University Hospital, Lille, Centre Hospitalier Universitaire de Nice, University Hospital, Caen, University Hospital, Toulouse, University Hospital, Tours, Nantes University Hospital, Groupe Hospitalier Pitie-Salpetriere, Hospices Civils de Lyon, University Hospital, Montpellier, University Hospital, Strasbourg, Central Hospital, Nancy, France, HOSPITAL, CHARTRES, University of Liege | Type2 Diabetes, Diabetic Kidney Disease | 09/23 | 12/23 | | |
AAREN, NCT05107388: Continuous Glucose Monitoring Profile Description Under Alpelisib treAtment in Patients With Advanced bREast Cancer |
|
|
| Not yet recruiting | N/A | 40 | Europe | FreeStyle Libre Pro | Centre Hospitalier Universitaire de Besancon | Breast Cancer, Diabetes | 01/24 | 03/24 | | |
| Recruiting | N/A | 160 | Europe | Insulin Management System in Manual mode of operation, Insulin Management System in Automatic mode of operation | Medtrum France, Axonal-Biostatem | Type 1 Diabetes | 11/25 | 12/25 | | |
NCT05893797: A Study of LY8888AX in Participants Using a Connected Insulin Management Platform |
|
|
| Completed | N/A | 36 | Europe | Insulin Lispro, Humalog Tempo Pen, Tempo Smart Button, Dexcom G6 CGM, Glooko Research Medical App (RMA) | Eli Lilly and Company | Type 1 Diabetes, Type 2 Diabetes, Type 2 Diabetes Treated With Insulin | 09/24 | 09/24 | | |
GLUCOGEN, NCT06570278: Role of High-Throughput Whole Genome Sequencing for the Diagnosis and Care of Atypical Diabetes |
|
|
| Recruiting | N/A | 1020 | Europe | WGS coupled with MCM | Institut National de la Santé Et de la Recherche Médicale, France, Commissariat A L'energie Atomique, Rennes University Hospital, Central Hospital, Nancy, France, Nantes University Hospital, Imagine Institute, APHP, Hospices Civils de Lyon, Université Lumière Lyon 2, Toulouse University Hospital | Diabetes Mellitus | 11/31 | 11/34 | | |
| Recruiting | N/A | 3000 | Europe | No intervention | European Georges Pompidou Hospital, Oscar - Filière Santé Maladies Rares | Hypoparathyroidism | 09/30 | 09/31 | | |
| Mansi, Laura |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
RAINBO-RED, NCT06712472: Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for P53abn Endometrial Cancer |
|
|
| Recruiting | 3 | 554 | Europe | Olaparib (300 mg BID) | Gustave Roussy, Cancer Campus, Grand Paris, AstraZeneca | Endometrial Cancer, P53abn | 06/30 | 12/31 | | |
SALVOVAR, NCT06476184: Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery |
|
|
| Recruiting | 3 | 250 | Europe, Japan | Carboplatin, Paclitaxel | ARCAGY/ GINECO GROUP, Horizon 2020 - European Commission | Ovarian Cancer | 06/27 | 06/28 | | |
| Recruiting | 3 | 538 | Europe, US | cisplatin | The Netherlands Cancer Institute | Ovarian Cancer | 04/25 | 04/26 | | |
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation |
|
|
| Recruiting | 3 | 500 | Europe, Canada, US, RoW | Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib | Sermonix Pharmaceuticals Inc. | Metastatic Breast Cancer | 04/27 | 04/28 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
RAMP 301, NCT06072781: A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer |
|
|
| Recruiting | 3 | 270 | Europe, Canada, US, RoW | avutometinib, avutometinib (VS-6766), Defactinib, defactinib (VS-6063), Pegylated liposomal doxorubicin, Caelyx, Doxil, Lipodox, Paclitaxel, Nov-Onxol, Onxol, Navaplus, Taxol, Letrozole, Femara, Anastrozole, Arimidex | Verastem, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Australia New Zealand Gynaecological Oncology Group | Low Grade Serous Ovarian Cancer | 10/28 | 02/31 | | |
GUIDE2REPAIR, NCT04169841: Study Evaluating the Efficacy of a Double Immunotherapy Combined With Olaparib in Patients With Solid Cancers and Carriers of Homologous Recombination Repair Genes After Olaparib Treatment |
|
|
| Active, not recruiting | 2 | 270 | Europe | olaparib, durvalumab, tremelimumab | Centre Georges Francois Leclerc, AstraZeneca | Immunotherapy | 08/27 | 08/27 | | |
| Recruiting | 2 | 390 | Europe, Japan, RoW | Chemotherapy, Bevacizumab-Awwb, Niraparib | ARCAGY/ GINECO GROUP, GSK | Ovarian Cancer | 02/27 | 02/30 | | |
COLIBRI-2, NCT06715241: A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS |
|
|
| Recruiting | 2 | 77 | Europe | combination of relatlimab and nivolumab wich are two immunotherapy treatments, Nivolumab alone | ARCAGY/ GINECO GROUP | LOCALLY ADVANCED CERVICAL CANCERS | 12/30 | 12/30 | | |
| Active, not recruiting | 2 | 180 | Europe | OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475 | ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC | Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer | 12/25 | 12/25 | | |
EXOMA2, NCT04614480: Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine |
|
|
| Recruiting | 2 | 2518 | Europe | Exome analysis | Centre Georges Francois Leclerc | Cancer | 09/25 | 09/29 | | |
| Recruiting | 2 | 1100 | Europe | Ribociclib (neoadjuvant), Kisqali, Chemotherapy (adjuvant), Ribociclib (adjuvant) | SOLTI Breast Cancer Research Group, Novartis, UNICANCER | Breast Cancer Stage II | 10/29 | 12/31 | | |
ITHER, NCT02840058: Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1 |
|
|
| Recruiting | N/A | 120 | Europe | Biological samples, Anti PD1/PDL1 treatment | Centre Hospitalier Universitaire de Besancon | Cancer | 03/22 | 12/22 | | |
| Recruiting | N/A | 300 | Europe | Additional biological samples | Centre Hospitalier Universitaire de Besancon | Cancer, Elderly, Healthy Aging | 03/22 | 03/23 | | |
| Active, not recruiting | N/A | 50 | Europe | blood samples | Centre Georges Francois Leclerc | Ovarian Cancer | 11/22 | 11/24 | | |
KELI-PAOLA, NCT06660147: Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer |
|
|
| Recruiting | N/A | 327 | Europe, RoW | | ARCAGY/ GINECO GROUP | Ovarian Cancer | 12/24 | 12/24 | | |
AFTERGYN2, NCT06553612: Impact of a Multidisciplinary Assessment in Day Hospitalization Versus Standard Care on the Deployment of Supportive Oncology Care Recommended by the Personalized Post-cancer Plan in Patients At the End of Initial Treatment for Gynecological Ovarian and Endometrial Cancer Endometrial Cancer |
|
|
| Recruiting | N/A | 268 | Europe | Multidisciplinary assessment, Standard assesment, Observational cohort | Centre Francois Baclesse | Gynecologic Cancer, Remission | 09/27 | 06/28 | | |
LARENA, NCT06599463: Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study |
|
|
| Recruiting | N/A | 250 | Europe | | ARCAGY/ GINECO GROUP, Institut Curie | Metastatic Endometrial Cancer | 12/24 | 12/24 | | |
| VIENOT, Angélique |
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer |
|
|
| Recruiting | 2/3 | 600 | Europe, US, RoW | SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo | Panbela Therapeutics, Inc. | Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV | 08/26 | 01/27 | | |
SPARTANA, NCT04894370: Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma |
|
|
| Recruiting | 2 | 34 | Europe | Sample collection | Centre Hospitalier Universitaire de Besancon, National Cancer Institute, France, Novartis | Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma | 06/25 | 11/26 | | |
CLavSyn, NCT03117972: Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels |
|
|
| Terminated | 2 | 54 | Europe | FOLFOXIRI, Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, FOLFOX, FOLFIRI, Ironotecan, Bevacizumab, LV5FU2, Capecitabine | Centre Hospitalier Universitaire de Besancon | Metastatic Colorectal Cancer | 08/24 | 11/24 | | |
ALIX, NCT03974854: Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma |
|
|
| Terminated | 2 | 25 | Europe | XELOXIRI-3, Capecitabine, Oxaliplatine, Irinotecan, Gemcitabine | Centre Hospitalier Universitaire de Besancon | Metastatic Pancreatic Adenocarcinoma | 08/23 | 02/24 | | |
INTERACT-ION, NCT04719988: Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma. |
|
|
| Active, not recruiting | 2 | 55 | Europe | Blood sample collection, Biopsy | Centre Hospitalier Universitaire de Besancon, Boehringer Ingelheim | Squamous Cell Carcinoma of the Anus Stage III | 11/24 | 07/26 | | |
CARE, NCT06425133: Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers |
|
|
| Recruiting | 2 | 174 | Europe | Blood sample, Quality of life questionnaires, Biopsy, Regorafenib, Regorafenib + metronomic chemotherapy | Centre Hospitalier Universitaire de Besancon, Groupement Interrégional de Recherche Clinique et d'Innovation | Metastatic Colorectal Cancer | 09/27 | 09/28 | | |
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (non-colorectal/non-endometrial) with Tumor DMMR/MSI |
|
|
| Recruiting | 2 | 120 | Europe | Dostarlimab, Chemotherapy | UNICANCER, National Cancer Institute, France, GlaxoSmithKline | Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma | 10/28 | 09/30 | | |
PREMICES, NCT06646445: Neoadjuvant Pembrolizumab with a Watch-and-wait Strategy for Patients with DMMR/MSI-H Localized Colon Cancer: GERCOR G-109 PRODIGE 84 Phase II Trial |
|
|
| Not yet recruiting | 2 | 64 | Europe | Pembrolizumab 200mg IV q3w day 1 of 21-day cycle, Keytruda, Watch-and-wait approach, Surgery, Adjuvant chemotherapy | GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD | Colon Cancer | 10/27 | 10/29 | | |
| Recruiting | 2 | 30 | Europe | Nivolumab, Ipilimumab | GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol Myers Squibb | Metastatic Colorectal Cancer | 12/24 | 09/27 | | |
FUDOSE, NCT06475352: Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme |
|
|
| Recruiting | 2 | 400 | Europe | FOLFOX regimen, CAPOX regimen | UNICANCER | Digestive Cancer, Colorectal Cancer | 04/27 | 01/30 | | |
PANORAMA, NCT06397846: Identification of Biomarkers Associated With the Presence of Malignant Pancreatic Lesions Compared to Benign Lesions. |
|
|
| Recruiting | N/A | 100 | Europe | Biological sample | Centre Hospitalier Universitaire de Besancon | Benign Pancreatic Lesion | 12/26 | 06/27 | | |
NCT04935853: Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study |
|
|
| Recruiting | N/A | 1350 | Europe | | GERCOR - Multidisciplinary Oncology Cooperative Group | Biliary Tract Cancer | 06/30 | 06/40 | | |
| Recruiting | N/A | 4050 | Europe | | GERCOR - Multidisciplinary Oncology Cooperative Group | Pancreatic Adenocarcinoma | 12/30 | 12/31 | | |
| Vienot, Angelique |
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma |
|
|
| Recruiting | 3 | 200 | Europe, US, RoW | Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma | 05/26 | 08/26 | | |
ALIX, NCT03974854: Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma |
|
|
| Terminated | 2 | 25 | Europe | XELOXIRI-3, Capecitabine, Oxaliplatine, Irinotecan, Gemcitabine | Centre Hospitalier Universitaire de Besancon | Metastatic Pancreatic Adenocarcinoma | 08/23 | 02/24 | | |
BIG, NCT06253611: First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer |
|
|
| Recruiting | 2 | 120 | Europe | Nivolumab, Opdivo, FOLFOX regimen, Leucovorin, fluorouracil, and oxaliplatin, EXL01 | GERCOR - Multidisciplinary Oncology Cooperative Group | Gastric Cancer | 03/26 | 03/29 | | |
| Active, not recruiting | 2 | 350 | Europe, Canada, US | 9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar | Actuate Therapeutics Inc., Actuate Therapeutics Inc | Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma | 01/25 | 01/26 | | |
| Recruiting | N/A | 4050 | Europe | | GERCOR - Multidisciplinary Oncology Cooperative Group | Pancreatic Adenocarcinoma | 12/30 | 12/31 | | |
